-
Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy + Edodekin Alfa in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy + Edodekin Alfa in Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy + Edodekin Alfa in...
-
Likelihood of Approval and Phase Transition Success Rate Model - EEDVD-682 in Kidney Cancer (Renal Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EEDVD-682 in Kidney Cancer (Renal Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EEDVD-682 in Kidney Cancer (Renal Cell Cancer) Drug...
-
Likelihood of Approval and Phase Transition Success Rate Model - Abiraterone in Castration-Resistant Prostate Cancer (CRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abiraterone in Castration-Resistant Prostate Cancer (CRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abiraterone in Castration-Resistant Prostate Cancer (CRPC) Drug Details: Abiraterone...
-
Likelihood of Approval and Phase Transition Success Rate Model - AB-001 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AB-001 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AB-001 in Triple-Negative Breast Cancer (TNBC) Drug Details: AB-001...
-
Likelihood of Approval and Phase Transition Success Rate Model - Imiquimod + Zalifrelimab in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imiquimod + Zalifrelimab in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imiquimod +...
-
Likelihood of Approval and Phase Transition Success Rate Model - SPL-026 in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPL-026 in Major Depressive Disorder report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SPL-026 in Major Depressive Disorder Drug Details: SPL-026 is under...
-
Likelihood of Approval and Phase Transition Success Rate Model - OMS-1029 in Unspecified Immunological Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OMS-1029 in Unspecified Immunological Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OMS-1029 in Unspecified Immunological Disorders Drug Details: OMS-1029 is under...
-
Likelihood of Approval and Phase Transition Success Rate Model - IM-19 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IM-19 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IM-19 in Diffuse Large B-Cell Lymphoma Drug Details: IM-19...
-
Likelihood of Approval and Phase Transition Success Rate Model - ABL-103 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABL-103 in Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABL-103 in Inflammation Drug Details: ABL-103 is under development for the treatment...
-
Likelihood of Approval and Phase Transition Success Rate Model - [Sn-117m]-DOTA-Annexin V in Atherosclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - [Sn-117m]-DOTA-Annexin V in Atherosclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. [Sn-117m]-DOTA-Annexin V in Atherosclerosis Drug Details: Sn-117m-DOTA-Annexin V is under development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.